prof. dr. Fritz Offner

Conference Paper

Five-Year Update of the Phase 2 ELARA Trial of Tisagenlecleucel in Patients (pts) with relapsed/ refractory Follicular Lymphoma (r/r FL)

Stephen J. Schuster, Catherine Thieblemont, Michael J. Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, et al.

(2026) TRANSPLANTATION AND CELLULAR THERAPY. 32(2). p.S49-S50

Add to list

Conference Paper

Biomarker tail genes in blood plasma cell-free RNA enable accurate detection of prostate cancer

Annelien Morlion, Philippe Decruyenaere (UGent) , Kathleen Schoofs, Jasper Anckaert, Nickolas J. Ramirez, Justine Nuytens, Eveline Vanden Eynde, Kimberly Verniers, Celine Everaert, Guy Brusselle (UGent) , et al.

(2026) CANCER RESEARCH. 86(7).

Add to list

Journal Article
A2
open access

Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls

Annelien Morlion (UGent) , Philippe Decruyenaere (UGent) , Kathleen Schoofs (UGent) , Jasper Anckaert (UGent) , Nickolas Johns Ramirez (UGent) , Justine Nuytens (UGent) , Eveline Vanden Eynde (UGent) , Kimberly Verniers (UGent) , Celine Everaert (UGent) , Guy Brusselle (UGent) , et al.

(2026) COMMUNICATIONS MEDICINE. 6(1).

Add to list

Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1) : findings from a single-arm, multicentre, open-label, phase 1b/2 trial

Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner (UGent) , Jose D. Sandoval-Sus, Mazyar Shadman, Christian Bjorn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, Meijian Guan, et al.

(2026) LANCET HAEMATOLOGY. 13(1). p.e8-e21

Add to list

Conference Paper

Glofitamab Induces High Response Rates and Durable Remissions in Patients With Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those With a Poor Prognosis: Subgroup Results From a Phase 1/2 Trial

Tycel Phillips, Marek Trneny, Carmelo Carlo-Stella, Jan Zaucha, Tomasz Wrobel, Fritz Offner (UGent) , Michael Dickinson, Monica Tani, Michael Crump, Nancy L. Bartlett, et al.

(2025) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 25.

Add to list

Real-world evaluation of treatments and outcomes of follicular lymphoma in Belgium

Willem Daneels (UGent) , Gustaaf Claeys, Yaro Preem and Fritz Offner (UGent)

(2025) HEMATOLOGICAL ONCOLOGY. In Hematological Oncology 43(Supplement 3). p.73-74

Add to list

Epcoritamab monotherapy in relapsed/refractory chronic lymphocytic leukemia : EPCORE CLL-1 expansion and optimization data

Ewan Robson, Alexey Danilov, Bita Fakhri, Farrukh Awan, Hans Herluf Bentzen, Herbert Eradat, Carsten Utoft Niemann, Fritz Offner (UGent) , Christian Bjorn Poulsen, Thor Hoyer, et al.

(2025) BRITISH JOURNAL OF HAEMATOLOGY. In British Journal of Haematology 206(Supplement 1). p.382-383

Add to list

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma : EPCORE NHL-2 update

Lorenzo Falchi, Fritz Offner (UGent) , Sven de Vos, Joshua D. Brody, Raul Cordoba, Kim M. Linton, Sylvia Snauwaert, Michael Roost Clausen, Toshihiko Oki, Andrew J. Steele, et al.

(2025) BRITISH JOURNAL OF HAEMATOLOGY. In British Journal of Haematology 206(Supplement 1). p.185-185

Add to list

Glofitamab in patients with heavily pretreated relapsed/refractory mantle cell lymphoma : phase I/II study subgroup results

Dr Toby Eyre, Tycel Phillips, Mark Trneny, Carmelo Carlo-Stella, Jan Zaucha, Tomasz Wrobel, Fritz Offner (UGent) , Michael Dickinson, Monica Tani, Michael Crump, et al.

(2025) BRITISH JOURNAL OF HAEMATOLOGY. In British Journal of Haematology 206(Supplement 1). p.204-205

Add to list

LOTIS-7 : phase 1b study of loncastuximab tesirine with other agents in relapsed/refractory B-cell NHL

Emily C. Ayers, Julien Depaus, Fritz Offner (UGent) , Marie Hu, Craig Okada, Andrzej Urban, Andrew Niewiarowski, Erica Rave, Mary Laughlin, Juan Pablo Alderuccio, et al.

(2025) BRITISH JOURNAL OF HAEMATOLOGY. In British Journal of Haematology 206(Supplement 1). p.389-389

Academic Bibliography

prof. dr. Fritz Offner

Five-Year Update of the Phase 2 ELARA Trial of Tisagenlecleucel in Patients (pts) with relapsed/ refractory Follicular Lymphoma (r/r FL)

Biomarker tail genes in blood plasma cell-free RNA enable accurate detection of prostate cancer

Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls

Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1) : findings from a single-arm, multicentre, open-label, phase 1b/2 trial

Glofitamab Induces High Response Rates and Durable Remissions in Patients With Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those With a Poor Prognosis: Subgroup Results From a Phase 1/2 Trial

Real-world evaluation of treatments and outcomes of follicular lymphoma in Belgium

Epcoritamab monotherapy in relapsed/refractory chronic lymphocytic leukemia : EPCORE CLL-1 expansion and optimization data

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma : EPCORE NHL-2 update

Glofitamab in patients with heavily pretreated relapsed/refractory mantle cell lymphoma : phase I/II study subgroup results

LOTIS-7 : phase 1b study of loncastuximab tesirine with other agents in relapsed/refractory B-cell NHL

Contents

Support

Contact